Dep. of Neurosurgery, Bern University Hospital
Bern, 3000, Switzerland
Location status: Recruiting
Location contact
Andreas Nowacki, MD
CONTACT
Andreas Nowacki, MD
SUB_INVESTIGATOR
Claudio Pollo, MD
CONTACT
Claudio Pollo, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT05335668
Central poststroke pain (CPP) is estimated to affect up to 10% of stroke patients and is one of the most difficult-to-treat conditions with a detrimental effect on patient's quality of life. So far, no drug has proven efficient to alleviate CPP and neuromodulation approaches including Deep Brain Stimulation (DBS) and motor-cortex stimulation have yielded mixed results with only a few patients experiencing long-term pain relief. To date, little is known about the pathophysiology of CPP. There is at present little evidence for a clear association between the specific location of lesions, clinical manifestation and phenomenology of pain as well as treatment response of CPP patients. Furthermore, the time delay between stroke occurrence and CPP occurrence is highly variable and the fact, that it is not immediate in the great majority of patients suggests that other factors contribute to the development of CPP. These factors have not been identified yet.
Interested in participating?
Request Info18 year–75 year
All sexes
Interventional
Not applicable
Bern, 3000, Switzerland
Location status: Recruiting
Andreas Nowacki, MD
CONTACT
Andreas Nowacki, MD
SUB_INVESTIGATOR
Claudio Pollo, MD
CONTACT
Claudio Pollo, MD
PRINCIPAL_INVESTIGATOR
Central poststroke pain (CPP) is estimated to affect up to 10% of stroke patients and is one of the most difficult-to-treat conditions with a detrimental effect on patient's quality of life. So far, no drug has proven efficient to alleviate CPP and neuromodulation approaches including DBS and motor-cortex stimulation have yielded mixed results with only a few patients experiencing long-term pain relief. To date, little is known about the pathophysiology of CPP. There is at present little evidence for a clear association between the specific location of lesions, clinical manifestation and phenomenology of pain as well as treatment response of CPP patients. Furthermore, the time delay between stroke occurrence and CPP occurrence is highly variable and the fact, that it is not immediate in the great majority of patients suggests that other factors contribute to the development of CPP. These factors have not been identified yet.
The objective of this research project is to correlate clinical aspects of CPP (pain phenomenology) with magnetic resonance image (MRI)-based findings, especially metabolic changes and functional reorganization processes captured by functional MRI and MR spectroscopy. A better understanding of the underlying pathophysiological mechanism of CPP and its involved neuronal networks are mandatory for any future therapeutic approach to treat this difficult condition. The discovery of a potential image-based biomarker could serve to help identify patients early who are at risk of developing CPP. Furthermore, the findings may help identify prognosticators of different forms of CPP treatments (e.g. biofeed-back, neuromodulation approaches, medication) in the future.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
patients:
Exclusion criteria
patients:
Inclusion criteria
for healthy volunteers
Exclusion criteria
for healthy volunteers
Clinical testing for neurological deficits based on National Institute of Health Stroke Scale (NIHSS), objective sensory testing and pain assessment by quantitative sensory testing (QST) and quantitative pain drawings, 7T magnetic resonance imaging (MRI)
Time frame: Day 30 after inclusion
Correlation between cerebral connectivity patterns at rest during pain-processing tasks based on functional MRI
Contact information is provided by the study sponsor or research team.
Andreas Nowacki, MD
CONTACT
Claudio Pollo, MD
CONTACT
Insel Gruppe AG, University Hospital Bern
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06926933
CPP
Ansan, South Korea
View Trial DetailsNCT05563792
Agnosia, Chronic Pain
Indianapolis, Indiana, United States
View Trial DetailsNCT07226700
Agnosia, JOURNAVX
New York, United States
View Trial DetailsNCT02446262
Healthy Volunteers, Neurologic Manifestations
Bethesda, Maryland, United States
View Trial Details